Logo

PharmaShots Interview: Clario’s Lynne Borthwick Shares Insight on Winning Top Workplace Award by Energage

Share this

PharmaShots Interview: Clario’s Lynne Borthwick Shares Insight on Winning Top Workplace Award by Energage

In an interview with PharmaShots, Lynne Borthwick, EVP and Chief People Officer shared her views on receiving an honor of 2020 Top workplace by Energage. She also shared what this award means to Clario

Shots:

  • Clario is a great place to work as it helps partners in transforming lives by unlocking better evidence through clinical trial technology
  • Clario is committed to providing career growth and development opportunities with its “The Emerging Leaders Program”. This is an 8-month program targeting high performing Managers, Directors and Senior Directors
  • Clario has also committed to hiring 40 percent of people of color across all levels in 2022 and accelerating pay equity across the organization 

 

Tuba: What are the reasons that make Clario a great place to work? 

Lynne: I believe Clario is celebrated as a top place to work because we are a driver of positive impact. Based on our employee feedback, it is our people-centered culture and leadership combined with a strong purpose to help our partners transform lives by unlocking better evidence through clinical trial technology that makes us special. Our Clario employees also value feeling listened to and supported, and they appreciate the collaborative environment and culture of team building with leadership.

Tuba: How are you feeling after winning the 2020 Top workplace honor?   

Lynne: The award is rooted in employee feedback, so we are extremely proud and thankful to be recognized as a Top Workplace by those who know it best. As the Chief People Officer at Clario, I am especially pleased to see our core values resonating among our incredible employees. We strive to empower each team member and encourage everyone at Clario to take pride in the work that helps to create a positive change for so many.

Tuba: Discuss your Emerging Leaders Program with our readers.  

Lynne: Clario is committed to providing career growth and development opportunities in the company. A great example of this is The Emerging Leaders Program. This is an 8-month program targeted at high performing Managers, Directors and Senior Directors.  The program goals include achieving senior leadership bench strength, elevating strengths and closing development gaps, fostering a network of global leaders, and elevating more women and people of color into leadership positions.

Tuba: What does this award mean for Clario?

Lynne: Receiving this honor is a testament to how we uphold our core value of ‘People First Always.’ Our people are integral to fulfilling Clario’s mission of transforming lives both inside and outside our walls. As we continue to harness this excitement and implement solutions based on employee feedback, we look forward to onboarding even more talent who share in our passion and join our remarkable team. 

Tuba: Put some light on your company and its technology.

Lynne: Clario is committed to having a positive impact on global healthcare. We are a technology company that generates the richest clinical evidence by fusing scientific expertise and global scale into the broadest endpoint technology platform. We have mastered generating the reliable evidence needed to bring new medicines, medical devices and therapies to market. Led by over 200 therapeutic area experts, Clario actively delivers innovative technology solutions to meet clinical trial objectives.  

About Lynne Borthwick:

As Chief People Officer at Clario, Lynne believes that a positive employee experience translates to exceptional customer experience. Her mission is to drive innovation and collaboration and build an inclusive, dynamic culture with the best talent in the industry.  She brings to Clario organization, talent, and culture transformation expertise gained from human resources and business leadership roles, in companies including Wiley, Unisys and Accenture.

Image Source: Pexels

Related Post: PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions